On June 13-14, 2018, in Boston, Massachusetts, Ncardia will host its Annual U.S. User Symposium. The event will showcase the use of Ncardia’s flagship hiPSC-derived cardiac models (Cor.4U® and Pluricyte®) and its hiPSC-derived neural cell products by key leaders in pharma and research.
Importantly, it will explore how experts in the pharmaceutical and biotechnology industry and leading academic institutions are using Ncardia’s first in class cells and assays in drug discovery, safety and toxicology screening, disease modelling and bioengineering. It will also present current approaches to establish and define standards for these cellular models.
Expected to be widely attended by representatives from the pharmaceutical sector, symposium attendees will view case studies of iPS cells in drug development decision-making and biomedical research and have the opportunity to exchange and share experiences with their peers.
Who Should Attend the Annual U.S. User Symposium?
Covering a wide range of topics related to scientific and research applications of hiPSCs, Ncardia’s Annual U.S. User Symposium will attract individuals from across academia, biotech, and Big Pharma, as well as representatives from CROs. Topics to be covered include innovative predictive and translational safety assessment, 3D tissue modeling, novel biosensors, and high throughput drug screening, among others.
Importantly, the event will feature top experts from across the iPS cell field, including Ulrich Broeckel (Medical College of Wisconsin) and Laszlo Urban (Novartis), as well as a keynote talk by Greg Luerman and Felix von Haniel. As the VP of Business Development and Sales at Ncardia, Felix von Haniel will discuss the future directions of Ncardia as a global leader in improving drug discovery.
Ncardia is also hosting a networking dinner party at Post 390 the night of June 13th. It will be an opportunity for attendees to meet iPS cell scientists and thought leaders from across industry and academia, as well as learn from Ncardia experts how its technologies are providing more certainty and assurance throughout the drug development process.
Ncardia has a special rate available for rooms at the Boston Park Plaza Hotel where the meeting will be taking place.
As a bonus, the entire registration fee will also go towards your next order with Ncardia as a discount!
Who is Ncardia?
Ncardia is a worldwide recognise expert in stem cell and cardiac and neuro drug discovery. It was established in September 2017, following the merger of Pluriomics and Axiogenesis. Privately held, Ncardia is based in Belgium, The Netherlands, Germany and in the USA and has operations in Europe, the US and Japan. It produces and commercializes high-quality, fully functional hiPSC derived cardiovascular and neuronal cell types and develops and realizes electrophysiology, biochemistry and contraction based assays for predictive safety pharmacology, toxicology testing and drug efficacy screenings.
The combined business allowed Ncardia to build on over two decades of knowledge, stem cell product R&D and commercialization. It also made Ncardia the largest provider of iPS cells in Europe and one of the largest providers worldwide.
Ncardia believes that stem cell technology will help to get better medicines to patients faster. Therefore, the company develops, produces and commercializes highly predictive human cellular assay systems for safety and efficacy testing. The cardiac product portfolio encompasses a broad panel of hiPSC derived cardiomyocytes (Pluricyte®, Cor.4U® and vCor.4U®), as well cardiac fibroblasts (FibroCor.4U®). In addition, the company delivers the Cardioplate™ product line of quality-controlled ready to use assay plates. The neural cell portfolio contains the pan-neuronal product CNS.4U®, the peripheral neurons product Peri.4U®, and astrocyte product Astro.4U®. Moreover, Ncardia developed an extensive portfolio of predictive and translational services for cardiac safety assessment and drug efficacy screenings to even better support and optimize the success of its clients drug discovery projects.